Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Favorable coagulation profile with fondaparinux after hip surgery in elderly patients

Z. Kudrnová, J. Kvasnička, K. Kudrna, J. Mazoch, I. Malíková, Z. Zenáhlíková, M. Sudrová, R. Brzežková

. 2009 ; 90 (4) : 476-482. [pub] 20091017

Language English Country United States

Document type Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't

E-resources Online Full text

NLK ProQuest Central from 2001-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest) from 2001-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2001-01-01 to 1 year ago

Twenty-three patients with fondaparinux prophylaxis over 75 years of age who underwent hip fracture surgery were enrolled in the study. Fondaparinux sodium (2.5 mg) was administered subcutaneously 6 h postoperatively and then every 24 h for 28 days. Coagulation and inflammatory parameters were measured preoperatively, then 10 h, 2, 7, and 28 days postoperatively. Increased D-dimers, positive acute phase proteins, and IL-6, and decreased negative acute phase proteins were observed preoperatively (P < 0.05). Maximum values were reached 10 h postoperatively for IL-6 and D-dimer, and on postoperative days 2 and 7 for positive acute phase proteins (P < 0.05). Transferrin, prealbumin and antithrombin levels were lowest 10 h postoperatively and on postoperative day 2 (P < 0.05). Increased D-dimers, IL-6, and positive acute phase proteins, and decreased negative acute phase proteins persisted until postoperative day 28 (P < 0.05). Prothrombin fragments (F1 + 2) reached peak levels preoperatively and decreased gradually until postoperative day 28. Fondaparinux promoted the inhibition of thrombin generation, as documented by negative correlation between F1 + 2 and FXa inhibition (r = -0.46; P < 0.001). Fondaparinux-induced FXa inhibition increased gradually until postoperative day 28. This increase correlated positively with antithrombin activity (r = 0.4; P < 0.05). Fondaparinux prophylaxis counteracted pro-thrombogenic effect associated with hip fracture and subsequent surgery without severe bleeding complications.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12025506
003      
CZ-PrNML
005      
20130219174710.0
007      
ta
008      
120816e20091017xxu f 000 0#eng||
009      
AR
024    7_
$a 10.1007/s12185-009-0425-z $2 doi
035    __
$a (PubMed)19838769
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kovářová Kudrnová, Zuzana $7 xx0167016 $u Central Hematological Laboratory, Thrombotic Center of the General Teaching Hospital, 1st Medical School of Charles University, Karlovo námĕstí 32, 128 08 Prague 2, Czech Republic. kudrnovaz@seznam.cz
245    10
$a Favorable coagulation profile with fondaparinux after hip surgery in elderly patients / $c Z. Kudrnová, J. Kvasnička, K. Kudrna, J. Mazoch, I. Malíková, Z. Zenáhlíková, M. Sudrová, R. Brzežková
520    9_
$a Twenty-three patients with fondaparinux prophylaxis over 75 years of age who underwent hip fracture surgery were enrolled in the study. Fondaparinux sodium (2.5 mg) was administered subcutaneously 6 h postoperatively and then every 24 h for 28 days. Coagulation and inflammatory parameters were measured preoperatively, then 10 h, 2, 7, and 28 days postoperatively. Increased D-dimers, positive acute phase proteins, and IL-6, and decreased negative acute phase proteins were observed preoperatively (P < 0.05). Maximum values were reached 10 h postoperatively for IL-6 and D-dimer, and on postoperative days 2 and 7 for positive acute phase proteins (P < 0.05). Transferrin, prealbumin and antithrombin levels were lowest 10 h postoperatively and on postoperative day 2 (P < 0.05). Increased D-dimers, IL-6, and positive acute phase proteins, and decreased negative acute phase proteins persisted until postoperative day 28 (P < 0.05). Prothrombin fragments (F1 + 2) reached peak levels preoperatively and decreased gradually until postoperative day 28. Fondaparinux promoted the inhibition of thrombin generation, as documented by negative correlation between F1 + 2 and FXa inhibition (r = -0.46; P < 0.001). Fondaparinux-induced FXa inhibition increased gradually until postoperative day 28. This increase correlated positively with antithrombin activity (r = 0.4; P < 0.05). Fondaparinux prophylaxis counteracted pro-thrombogenic effect associated with hip fracture and subsequent surgery without severe bleeding complications.
650    _2
$a proteiny akutní fáze $x analýza $7 D000209
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antikoagulancia $x aplikace a dávkování $x terapeutické užití $7 D000925
650    _2
$a hemokoagulace $x účinky léků $7 D001777
650    _2
$a vyšetření krevní srážlivosti $7 D001780
650    _2
$a faktor Xa $7 D015951
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fraktury kyčle $x krev $x chirurgie $7 D006620
650    _2
$a lidé $7 D006801
650    _2
$a mediátory zánětu $x krev $7 D018836
650    _2
$a injekce subkutánní $7 D007279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a polysacharidy $x aplikace a dávkování $x terapeutické užití $7 D011134
650    _2
$a pooperační komplikace $x prevence a kontrola $7 D011183
650    _2
$a časové faktory $7 D013997
650    _2
$a žilní tromboembolie $x prevence a kontrola $7 D054556
650    _2
$a inhibitory faktoru Xa $7 D065427
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kvasnička, Jan, $d 1943- $7 mzk2003187694
700    1_
$a Kudrna, Karel, $d 1952- $7 xx0083627
700    1#
$a Mazoch, Jiří. $7 _BN003617
700    1_
$a Malíková, Ivana $7 xx0158297
700    1#
$a Zenáhlíková, Zuzana. $7 xx0281967
700    1_
$a Sudrová, Magda $7 xx0143938
700    1#
$a Brzežková, Radka. $7 xx0281968
773    0_
$w MED00002329 $t International journal of hematology $x 1865-3774 $g Roč. 90, č. 4 (20091017), s. 476-482
856    41
$u https://pubmed.ncbi.nlm.nih.gov/19838769 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120816 $b ABA008
991    __
$a 20130219174936 $b ABA008
999    __
$a ok $b bmc $g 947548 $s 782852
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2009 $b 90 $c 4 $d 476-482 $e 20091017 $i 1865-3774 $m International journal of hematology $n Int J Hematol $x MED00002329
LZP    __
$a Pubmed-20120816/10/02

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...